Fresenius Kabi competitors

Robert B. Ford is an American businessman and the thirteenth chief executive officer at Abbott Laboratories, a publicly-traded medical devices and health care company based in Abbott Park, Illinois. He received a bachelor's degree from Boston College and an MBA in business administration from the University of California, Berkeley, Haas School of Business.

José E. Almeida is a Brazilian businessman. He has served as the chairman and CEO of Baxter International, Inc. since January 2016. He worked for Tyco Healthcare from 1995 to 2002. He was president of Medical Devices division from October 2006 to June 2011. He served as chairman of the board of directors of Covidien since March 2012 and as the president, chief executive officer and a director since July 2011. He became a director of EMC Corporation on Jan 12, 2015 and resigned on October 30, 2015, due to his election as chairman and CEO of Baxter. In 2015, he worked for The Carlyle Group as an Operating Executive in the Global Healthcare group.

Terry Rich works at NUVASIVE INC and a President/CEO at RTI SURGICAL, INC. and Board Member at RTI SURGICAL, INC.. He has worked as Board Member at ALPHATEC HOLDINGS, INC.; Senior VP:Sales at NUVASIVE INC; and President/COO at ALPHATEC HOLDINGS, INC.. Terry attended Rutgers University.

Mr. Dominick C. Colangelo joined Promedior in December 2008 with fifteen years of pharmaceutical industry experience, including nearly a decade with Eli Lilly and Company. During his career, Mr. Colangelo has held a variety of executive positions of increasing responsibility in finance, product development, pharmaceutical operations, and corporate business development. During his tenure at Eli Lilly and Company, Mr. Colangelo held positions as an international tax attorney in the finance organization and as Director of Strategy and Business Development for Lilly’s Diabetes and Growth Disorders Product Group. He also served as a founding Managing Director of Lilly Ventures. Mr. Colangelo received a B.S.B.A. degree in Accounting from the State University of New York at Buffalo and a J.D. degree from the Duke University School of Law.

Jean-Claude Dubacher is Chairman and CEO of B. Braun of America Inc., which includes B. Braun Medical Inc., B. Braun Interventional Systems, Aesculap® and CAPS®. Mr. Dubacher joined B. Braun in August 2019 as President, B. Braun Medical Inc., and has served as Chairman and Chief Executive Officer of B. Braun Medical Inc. since January 1, 2020. Dubacher’s experience in healthcare spans more than 15 years in consulting and corporate roles including strategy, commercial, supply chain and manufacturing. Prior to joining B. Braun, Dubacher led commercial operations for the Surgical Ophthalmology Division of Johnson & Johnson (formerly Abbott Medical Optics) in Europe. Throughout his career, Mr. Dubacher has demonstrated a passion for focusing on customer needs and supporting people to be successful in developing, manufacturing, marketing, and selling products and services that benefit patients. Dubacher holds a Doctorate Degree in law (Dr. iur.) from the University of Zurich in Switzerland, and an MBA from Harvard Business School. He is a board member for the German American Chamber of Commerce.

Avi Pelossof was appointed Global President of our infectious disease business unit in March 2013, after serving as Vice President of that business from February 2008 to February 2013. Mr. Pelossof joined Alere as Vice President, Blood-Borne Pathogens in January 2007 and served in that role until January 2008. Mr. Pelossof has more than 20 years of experience in diagnostics, global health and international finance, including senior roles at Chembio Diagnostic Systems, a manufacturer of diagnostic tests for infectious diseases, and Citigroup.

Dr. Miller is a scientist, inventor, entrepreneur focused on Improving Lives with Precision Diagnostics® - coupling drug trials and therapeutic treatment regimens with optimized clinically-actionable diagnostic methods in order to select the correct patients and then monitor and track their response throughout the course of their disease. He received his undergraduate degree in Biochemistry from UCLA and a combined Ph.D. in Biochemistry & Molecular Biology from UCSB.